Announcing the TCT 2018 Late-Breaking Trials

NEW YORK – August 7, 2018 – The Cardiovascular Research Foundation (CRF) has announced the 15 late-breaking trials and 12 late-breaking clinical science presentations that will be reported at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place September 21 – 25, 2018 at the San Diego Convention Center in San Diego, California.

Every year, TCT features major medical research breakthroughs and highlights the latest data on the most innovative treatments that will impact patient care and how physicians treat heart disease, the leading cause of death in the world. The studies selected examine the safety and effectiveness of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease.

Late-breaking clinical trials and late-breaking science will be presented in the Main Arena and highlighted during press conferences scheduled for Saturday, September 22; Sunday, September 23; Monday, September 24; and Tuesday, September 25. TCT press conferences will be held each morning beginning at 7:30 AM PT.

The complete agenda for TCT 2018 is now available online at http://www.crf.org/tct/agenda/tct-2018-agenda. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty. Media are invited to attend TCT and can apply for media credentials online at: http://www.crf.org/tct/press/press-registration-form.

Saturday, September 22, 2018

Late-Breaking Trials

* IMPERIAL: A Randomized Trial of Drug-Eluting Stents for Treatment of Femoropopliteal Artery Lesions
William A. Gray

  • BIONYX: A Randomized Trial Evaluating an Ultra-Thin Strut Bioresorbable Polymer-Based Coronary Drug-Eluting Stent in an All-Comers Patient Population
    Clemens von Birgelen

  • ReCre8: A Randomized Trial Evaluating a Polymer-Free Coronary Drug-Eluting Stent in an All-Comers Patient Population
    Pieter R. Stella

    * LEADERS FREE II: Evaluation of a Polymer-Free Coronary Drug-Eluting Stent in High Bleeding-Risk Patients With One-Month Dual Antiplatelet Therapy
    Mitchell W. Krucoff

  • TALENT: A Randomized Trial Evaluating an Ultra-Thin Strut Bioresorbable Polymer-Based Coronary Drug-Eluting Stent in an All-Comers Patient Population
    Patrick W. Serruys

  • SORT OUT IX: A Randomized Trial Comparing a Polymer-Free Coronary Drug-Eluting Stent With an Ultra-Thin Strut Bioresorbable Polymer-Based Drug-Eluting Stent in an All-Comers Patient Population
    Lisette Okkels Jensen

Sunday, September 23, 2018

Late-Breaking Trials

* COAPT: A Randomized Trial of Transcatheter Mitral Valve Leaflet Approximation in Patients With Heart Failure and Secondary Mitral Regurgitation
Gregg W. Stone

* REDUCE-FMR: A Sham-Controlled Randomized Trial of Transcatheter Mitral Valve Indirect Annuloplasty in Patients With Heart Failure and Secondary Mitral Regurgitation
Horst Sievert

* SOLVE-TAVI: A 2×2 Randomized Trial of Self-Expandable vs Balloon-Expandable Valves and General vs Local Anesthesia in Patients Undergoing Transcatheter Aortic Valve Implantation
Holger Thiele

  <strong><p>Late-Breaking Clinical Science</p></strong>  <p>*    PADN-5: A Randomized Trial of Pulmonary Artery Denervation in Patients With Combined Pre- and Postcapillary Pulmonary Hypertension  <br />Shao-Liang Chen  
  • PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve
    John G. Webb

  • Prosthesis-Patient Mismatch: Incidence, Predictors, and Outcome of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement
    Howard C. Herrmann

  • TRIVALVE: Evaluation of Edge-to-Edge Valve Repair for Symptomatic Tricuspid Regurgitation
    Jörg Hausleiter

    Monday, September 24, 2018

    Late-Breaking Trials

    * ULTIMATE: A Randomized Trial of Intravascular Ultrasound Guidance of Coronary Drug-Eluting Stent Implantation in an All-Comers Patient Population
    Junjie Zhang

  • LRP: Assessment of Coronary Near-Infrared Spectroscopy Imaging to Detect Vulnerable Plaques and Vulnerable Patients
    Ron Waksman

  • OAC ALONE: A Randomized Trial of Oral Anticoagulation With vs Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation Beyond One Year After Drug-Eluting Stent Implantation
    Yukiko Nakano

Late-Breaking Clinical Science

  • FAST-FFR: Accuracy of Fractional Flow Reserve Derived From Coronary Angiography
    William F. Fearon

  • SYNTAXES: Ten-Year Follow-up From a Randomized Trial of Drug-Eluting Stents vs Bypass Surgery in Patients With Left Main and Triple Vessel Disease
    Daniel J.F.M. Thuijs

  • MAIN-COMPARE: Ten-Year Follow-up From a Nonrandomized Trial of Drug-Eluting Stents vs Bypass Surgery in Patients With Left Main Disease
    Seung-Jung Park

  • PREPARE-CALC: A Randomized Trial of High-speed Rotational Atherectomy Prior to Drug-Eluting Stent Implantation in Severely Calcified Coronary Lesions
    Gert Richardt

    Tuesday, September 25, 2018

    Late-Breaking Trials

    * ABSORB IV: A Blinded Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in an Expanded Patient Population Using Optimized Technique
    Gregg W. Stone

  • COMPARE ABSORB: A Randomized Trial of a Polymeric Everolimus-Eluting Bioresorbable Scaffold in High-Risk and Complex Lesions
    Pieter C. Smits

  • RADIOSOUND-HTN: A Three-Arm Randomized Trial of Different Renal Denervation Devices and Techniques in Patients With Resistant Hypertension
    Philipp Lurz

    Late-Breaking Clinical Science

    * CorMicA: A Randomized Trial of Invasive Coronary Function Testing in Patients With Angina and Nonobstructive Coronary Artery Disease
    Tom J. Ford

  • RESET: Seven-Year Follow-up From a Randomized Trial of Sirolimus-Eluting vs Everolimus-Eluting Stents in Patients With Coronary Artery Disease
    Hiroki Shiomi

  • NEOPRO: Nonrandomized Comparison of Two Transcatheter Heart Valve in Patients With Severe Aortic Stenosis
    Matteo Pagnesi

  • PORTICO I: One-Year Outcomes With a Self-Expanding, Repositionable Transcatheter Heart Valve in Patients With Severe Aortic Stenosis
    Lars Sondergaard

###

<p>Receive updates on Twitter at http://twitter.com/TCTConference and http://twitter.com/crfheart.</p>      <strong><p>About CRF and TCT</p></strong>  <p>The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and educated doctors on the latest treatments for heart disease. </p>    <p>Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. Now in its 30th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field.</p>      <p>For more information, visit http://www.crf.org and http://www.tctconference.com.</p>                                    <p><strong>Media Contact</strong></p>    <p>Judy Romero<br />[email protected]<br /> @CRFHeart     

http://www.crf.org

       http://www.crf.org/crf/news-and-events/news/news/2677-announcing-the-tct-2018-late-breaking-trials 
Comments
%d bloggers like this: